cytochrome P450 family 4 subfamily F member 24, pseudogeneGenealiases: []
Q-omics provides the consensus-scored CYP4F24P profile across patient tissues and cancer cell-line models. CYP4F24P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, CYP4F24P is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, CYP4F24P RNA expression shows 9,950 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight THYM, COAD, and TGCT as cancer lineages where CYP4F24P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP4F24P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP4F24P survival associations across molecular data types. CYP4F24P RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP4F24P RNA expression–survival associations across cancer types. High CYP4F24P expression shows unfavorable associations in THYM, KIRC, COAD and THCA, but favorable associations in READ and PAAD. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for CYP4F24P RNA expression.
This table summarizes CYP4F24P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CYP4F24P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP4F24P shows lower tumor expression in COAD, KIRP, HNSC, UCEC, BRCA and LUSC. The COAD box plot shows higher CYP4F24P RNA expression in normal versus tumor tissue (log2 FC = −0.542, t-test p < 0.001).
This table shows molecular features associated with CYP4F24P in patient tissues and cancer cell lines. In patient samples, CYP4F24P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP4F24P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS.
